Integrated Diagnostics Holdings PLC Cancellation of Treasury Shares

RNS Number : 4282H

Integrated Diagnostics Holdings PLC

08 October 2024

 

 

Integrated Diagnostics Holdings plc

(the "Company")

 

Cancellation of Treasury Shares

     

08 October 2024

 

The Company today announces the cancellation of 18,673,728 treasury shares initially transferred to treasury on the Completion of Treasury Shares Removal Process referred to in the Company's announcement on 18 September 2024.

 

In accordance with Listing Rule 9.8.2 the Company discloses the following information:

 

Date of cancellation	08 October 2024
Number of ordinary shares held in treasury cancelled	18,673,728
Total number of ordinary shares held in treasury following the cancellation	0
Total number of ordinary shares in issue following the cancellation (excluding shares held in treasury)	581,326,272

 

For further information please contact:

Integrated Diagnostics Holdings plc

Tarek Yehia

Investor Relations Director

T: [phone] | M: [phone] |    [e-mail]

 

Company Secretary

Company Matters

[e-mail]

 

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

 IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Sudan and Saudi Arabia. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Biolab KSA (Saudi Arabia).  With over 40 years of experience, a long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 3 ,000 diagnostics tests. From its base of 601 branches as of 31 December 2023, IDH served over 8. 5 million patients and performed more than 36.1 million tests in 2023.  IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion.  Beyond organic growth, the Group targets expansion in appealing markets, including acquisitions in the Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets.  IDH is a Jersey-registered entity whose Shares are admitted to the equity shares (transition) category (previously, the standard listing segment) of the Official List of the UK Financial Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange since May 2015 (ticker: IDHC).

 

Learn more at idhcorp.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

POSUWANRSWURRAA